Azenta designates B Medical discontinued, expects sale by March 2026

Azenta designates B Medical as discontinued as it pursues sale

Azenta, a provider of sample management and multiomics services to the life‑sciences industry, is treating B Medical Systems as discontinued operations as it pursues a sale that follows an earlier first‑fiscal‑quarter 2025 announcement. The company reports that it has entered a definitive agreement and expects the sale to close on or before March 31, 2026. The move removes B Medical from continuing operations for the quarter ended Dec. 31, 2025 and frames the quarter’s results around Azenta’s core laboratory infrastructure businesses.

The designation signals a strategic streamlining of Azenta’s portfolio, concentrating reported performance on its Sample Management Solutions and Multiomics segments. Management presents continuing‑operations results separately and is positioning the divestiture as a way to simplify reporting and sharpen investment and operational focus on laboratory automation, storage and molecular services. The company’s disclosure makes clear the closing timeline and the intention to exclude B Medical from ongoing operating metrics once the transaction completes.

Market observers say the pending sale is the most consequential near‑term corporate action for Azenta because it materially alters the mix of revenue and assets that define the company’s growth profile. Once closed, the transaction will remove B Medical’s results from continuing operations and could free resources for capital allocation and R&D within Azenta’s remaining businesses, while also changing how future quarterly comparisons are constructed.

Continuing operations: revenue and segment detail

Revenue from continuing operations is $149.0 million for the quarter, down 7% from $159.0 million in the prior quarter and up 1% from $147.0 million a year earlier, with organic growth running negative 1%. By segment, Sample Management Solutions generates $81.0 million (down 5% sequentially from $86.0 million, unchanged year‑over‑year) and Multiomics records $67.0 million (down 8% sequentially from $73.0 million, up 1% from $66.0 million).

Profitability and adjusted results show pressure

Reported diluted EPS from continuing operations is $(0.11), compared with $1.12 in the prior quarter and $(0.16) a year earlier; total diluted EPS is $(0.34) versus $1.11 in the prior quarter and $(0.25) a year earlier. On a non‑GAAP basis, diluted EPS from continuing operations is $0.09 (versus $0.21 prior quarter and $0.12 prior year). Adjusted EBITDA from continuing operations is $13.0 million, down from $21.0 million in the prior quarter and $16.0 million a year earlier.